CytomX Therapeutics, Inc. (CTMX) AI Stock Analysis

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. The company uses its proprietary Probody platform to design antibody therapeutics that activate selectively within the tumor microenvironment. Its clinical pipeline includes CX-2009 in Phase II trials for breast cancer and CX-2029 in Phase II trials for squamous non-small cell lung cancer and head and neck carcinoma. CytomX is also advancing BMS-986249 and BMS-986288 in collaboration with Bristol-Myers Squibb, alongside CX-2043 and CX-904 for solid tumors. Strategic development partners include AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas Pharma.

Between FY2021 and FY2025, revenue registered a 5-year compound annual growth rate of 2.2%. Annual revenue peaked at $138.1M in FY2024 before falling 44.8% to $76.2M in FY2025. Gross margin remained at 100.0% throughout the 5-year period. Net income swung from $31.9M in FY2024 to -$17.4M in FY2025, accompanied by an operating margin of -29.3%. For the latest quarter ended June 30, 2026, quarterly revenue dropped 92.4% year-over-year, while quarterly earnings grew 60.6%. Trailing twelve months revenue stood at $18.3M with an operating margin of -1677.1% and diluted earnings per share of -$0.51.

As of June 30, 2026, CytomX held $330.3M in cash and short-term investments against total debt of $5.7M, yielding net cash of $324.6M. Total assets stood at $381.2M and shareholders' equity was $302.1M. The company reported a current ratio of 9.36 and a debt-to-equity ratio of 0.02. In FY2025, operating cash flow was -$75.6M and free cash flow was -$75.8M. Capital expenditures totaled $220,000 and dividends paid were $3.0M, while the share count increased 235.8% over five years.

CytomX trades at an enterprise value of $282.3M and a market capitalization of $496.8M. Its forward price-to-earnings multiple is 14.2x, below the median of its US-listed Healthcare peers of 17.3x. The stock trades at a price-to-sales multiple of 27.1x, higher than the peer median of 4.1x, and an enterprise value-to-EBITDA multiple of 8.7x compared to the peer median of 12.0x. Over the past year, the stock returned -30.5%, trailing the S&P 500 return of 16.8%, and fell 55.6% over five years versus an 83.0% gain for the index.

Wall Street coverage includes 5 Strong Buy and 3 Buy recommendations, with no Hold, Sell, or Strong Sell ratings. The mean price target is $12.25, representing a 437.3% premium to the last close of $2.28. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $25.0M and earnings per share of -$0.39. For the following fiscal year, 7 analysts project revenue of $25.3M. CytomX beat earnings expectations in 2 of the last 4 quarters, with the next earnings announcement scheduled for November 5, 2026.

This page is an AI-written research summary of CytomX Therapeutics, Inc. (CTMX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CTMX income statement, CTMX balance sheet, CTMX key metrics, CTMX analyst forecast, CTMX chart. See the CTMX stock overview for the latest quote and news.